Australian ports and rail operator Asciano on Tuesday recommended shareholders accept a US$6.3 billion takeover bid by a consortium including a Chinese sovereign wealth fund, leaving rival suitor Canadian asset manager Brookfield out in the cold.
Australian-led Qube Holdings — including China’s CIC Capital Corporation, the Canada Pension Plan Investment Board and investment group Global Infrastructure Partners — submitted a revised offer this month with an implied value of Aus$9.17 per Asciano share.
The move was a direct challenge to an earlier, inferior bid by Brookfield Infrastructure Partners, which has been chasing Asciano since July.
Brookfield’s initial approach last year came during a flurry of acquisitions in Australia’s transport sector — including Japan Post Holdings’ purchase of Toll Holdings — as the local dollar weakened and the nation’s conservative government pushed for infrastructure spending.
The Canadian asset manager had until Monday to match or beat Qube’s offer with Asciano, which handles nearly half of all container traffic entering or leaving Australia, switching preference after Brookfield failed to submit a revised bid.
“The Asciano board has determined that the Qube consortium proposal is superior to the proposal from Brookfield,” the company said in a market announcement.
Full content: The Financial Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Johns Hopkins and Caltech Settle for $35.3M in College Price-Fixing Lawsuit
Jan 22, 2025 by
CPI
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan